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Abstract
Introduction Acute lung injury (ALI) may arise both after sepsis
and non-septic inflammatory conditions and is often associated
with the release of fatty acids, including oleic acid (OA). Infusion
of OA has been used extensively to mimic ALI. Recent research
has revealed that intravenously administered recombinant
human activated protein C (rhAPC) is able to counteract ALI.
Our aim was to find out whether rhAPC dampens OA-induced
ALI in sheep.
Methods Twenty-two yearling sheep underwent instrumentation.
After 2 days of recovery, animals were randomly assigned to one of
three groups: (a) an OA+rhAPC group (n = 8) receiving OA 0.06
mL/kg infused over the course of 30 minutes in parallel with an
intravenous infusion of rhAPC 24 mg/kg per hour over the course
of 2 hours, (b) an OA group (n = 8) receiving OA as above, or (c) a
sham-operated group (n = 6). After 2 hours, sheep were sacrificed.
Hemodynamics was assessed by catheters in the pulmonary artery
and the aorta, and extravascular lung water index (EVLWI) was
determined with the single transpulmonary thermodilution
technique. Gas exchange was evaluated at baseline and at
cessation of the experiment. Data were analyzed by analysis of
variance; a P value of less than 0.05 was regarded as statistically
significant.
Results OA induced profound hypoxemia, increased right atrial
and pulmonary artery pressures and EVLWI markedly, and
decreased cardiac index. rhAPC counteracted the OA-induced
changes in EVLWI and arterial oxygenation and reduced the
OA-induced increments in right atrial and pulmonary artery
pressures.
Conclusions In ovine OA-induced lung injury, rhAPC dampens
the increase in pulmonary artery pressure and counteracts the
development of lung edema and the derangement of arterial
oxygenation.
Introduction
Mortality from acute lung injury (ALI) still remains between
30% and 40% [1]. Patients with acute respiratory distress
syndrome (ARDS), the most severe form of ALI, present with
elevated plasma concentrations of oleic acid (OA), which is
one of the most abundantly occurring fatty acids in human
plasma [2]. The proportion of OA increases in the bronchoal-
veolar lavage fluid of patients with pneumonia and ARDS [3].
In combination with sepsis, an enhanced plasma level of OA
adds to the risk of contracting ARDS [4]. However, independ-
ent of whether a high plasma concentration of OA contributes
to ARDS or not, infusion of OA has been widely used to mimic
non-septic lung injury in experimental settings. Administered to
animals, OA increases pulmonary vascular pressure and per-
meability, resulting in the development of lung edema and arte-
rial hypoxemia that are typical for this condition [5].
AaPO2: alveolar-arterial oxygen tension difference; ALI: acute lung injury; APC: activated protein C; ARDS: acute respiratory distress syndrome; CI: 
cardiac index; EVLWI: extravascular lung water index; HR: heart rate; IL: interleukin; iNOS: inducible nitric-oxide synthase; LVSWI: left ventricular 
stroke work index; MAP: mean systemic arterial pressure; OA: oleic acid; PaO2: partial tension of oxygen in arterial blood; PAOP: pulmonary arterial 
occlusion pressure; PAP: pulmonary arterial pressure; Pmo: pulmonary capillary micro-occlusion pressure; PVRI: pulmonary vascular resistance index; 
Qs/Qt: venous admixture; RAP: right atrial pressure; rhAPC: recombinant human activated protein C; RVSWI: right ventricular stroke work index; 
SaO2: arterial oxygen saturation; SVRI: systemic vascular resistance index.Critical Care    Vol 12 No 6    Waerhaug et al.
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Activated protein C (APC) antagonizes thrombin generation
by inactivating coagulation factors Va and VIIIa with protein S
as a co-factor [6,7]. It has been suggested that, by binding to
endothelial APC receptor (EPCR) and to protease activated
receptor-1 (PAR-1), APC initiates cytoprotective reactions,
gene expression profile alterations, and anti-inflammatory and
anti-apoptotic effects [8-11].
Recombinant human APC (rhAPC) increases survival from
severe sepsis [12]. Reportedly, patients receiving rhAPC
demonstrate a shorter duration of respiratory failure [13]. Pro-
tein C decreases markedly in patients with ALI, whether of
septic or non-septic origin, and a low plasma level of protein C
is associated with a poor clinical outcome [14,15]. We spec-
ulated that rhAPC could be of potential benefit in the treatment
of ALI. Recent studies of ovine sepsis or endotoxin-induced
ALI support this assumption [16-18], whereas others have
failed to demonstrate favorable effects either in animal [19-21]
or human [22] studies. Up to now, no one study has docu-
mented beneficial effects of APC on models of non-septic ALI.
The aim of the present study was to investigate whether intra-
venously administered rhAPC alleviates ovine OA-induced
lung injury, assessing changes in pulmonary hemodynamics,
extravascular lung water, and arterial oxygenation.
Materials and methods
The Norwegian Experimental Animal Board approved the
study according to the rules and regulations of the Helsinki
Convention for Use and Care of Animals.
Animal instrumentation
Twenty-two yearling sheep weighing 34.3 ± 7.5 kg (mean ±
standard deviation) were instrumented under general anesthe-
sia and treated postoperatively as described previously by our
group [23]. In brief, an 8.5-Fr introducer (CC-350B; Baxter,
Deerfield, IL, USA) was inserted percutaneously in the left
external jugular vein and a 5-Fr introducer (CP-07511-P;
Arrow International, Inc., Reading, PA, USA) was inserted into
the ipsilateral common carotid artery. After 1 to 3 days of
recovery, the sheep were placed in an experimental pen. A
flow-directed thermal dilution catheter (131HF7; Baxter) was
introduced into the pulmonary artery, and a 4-Fr thermistor
catheter (PV2014L16; Pulsion Medical Systems, München,
Germany) was introduced into the thoracic aorta. The cathe-
ters were connected to pressure transducers (Transpac®III;
Abbott Laboratories, Abbott Park, North Chicago, IL, USA)
and PV8115 (Pulsion Medical Systems).
Measurements and samples
Measurements were performed at 1-hour intervals. Mean pul-
monary arterial pressure (PAP), pulmonary arterial occlusion
pressure (PAOP), and mean right atrial pressure (RAP) were
recorded on a Gould Polygraph 6600 (Gould Instruments,
Cleveland, OH, USA). The pulmonary capillary micro-occlu-
sion pressure (Pmo) was determined as described previously
[24].
Heart rate (HR), mean systemic arterial pressure (MAP), car-
diac index (CI), systemic vascular resistance index (SVRI),
extravascular lung water index (EVLWI), and blood tempera-
ture were determined using a PiCCO plus monitor (Pulsion
Medical Systems), where EVLWI is calculated using the
transpulmonary thermodilution technique. Every value was cal-
culated as a mean of three measurements, each consisting of
a 10-mL bolus of ice-cold saline injected into the right atrium
randomly during the respiratory cycle.
Left ventricular stroke work index (LVSWI) was calculated as
LVSWI = 0.0136 × (MAP - PAOP) × CI/HR, and right ven-
tricular stroke work index (RVSWI) was calculated as RVSWI
= 0.0136 × (PAP - RAP) × CI/HR. Stroke volume index and
pulmonary vascular resistance index (PVRI) were calculated
using standard formulas.
Blood samples were drawn from the systemic (a) and the pul-
monary artery (v) lines and analyzed for blood gases and
hemoglobin (Rapid 860; Chiron Diagnostics Corporation,
East Walpole, MA, USA) at the beginning and the end of the
2-hour experiment. Assuming the hemoglobin oxygen binding
capacity to be 1.34 mL/g, oxygen delivery index (DO2I), oxy-
gen consumption index (VO2I), venous admixture (Qs/Qt), and
the alveolar-arterial oxygen tension difference (AaPO2) were
calculated as described previously [23].
Experimental protocol
After 2 days of recovery, animals were randomly assigned to
one of three groups: an OA+rhAPC group (n = 8) receiving
OA (Sigma-Aldrich, St. Louis, MO, USA) 0.06 mL/kg infused
over the course of 30 minutes in parallel with an intravenous
infusion of rhAPC (Xigris®; Eli Lilly and Company, Indianapolis,
IN, USA) 24 μg/kg per hour during the whole 2-hour experi-
ment, an OA group (n = 8) receiving OA as above, or a group
of sham-operated animals (n = 6). All sheep received a contin-
uous infusion of isotonic saline at 5 mL/kg per hour. After com-
pletion of the experiment, the sheep were killed with an
intravenous injection of thiopental sodium (Abbott) 100 mg/kg
followed by 50 mmol KCl (B. Braun Melsungen AG, Melsun-
gen, Germany).
Statistical analysis
Data are expressed as the mean ± standard error of the mean
and analyzed by two-factor analysis of variance for repeated
measurements. If F was statistically significant, Scheffe's test
was applied for post hoc analysis of the changes in time. Com-
parison between OA and OA+rhAPC groups was evaluated at
baseline (0 hours) and after 2 hours, applying the t test or the
Mann-Whitney test when appropriate (SPSS 15.0 for Win-
dows; LEAD Technologies, Charlotte, NC, USA). We
regarded P values of less than 0.05 as statistically significant.Available online http://ccforum.com/content/12/6/R146
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Results
All of the sheep survived the instrumentation and the experi-
ment without complications. Infusion of OA induced incre-
ments in EVLWI, PAP, and RAP that all declined significantly
during infusion of rhAPC (Figure 1). Moreover, MAP and SVRI
increased significantly (by 8% and 38%, respectively) with a
concomitant 25% decrease in CI, but none of these variables
was significantly influenced by rhAPC (Table 1). As the only
variable, PVRI differed between the groups at baseline (P <
0.05). Administration of rhAPC tended to reduce the OA-
induced increase in PVRI (Table 1), albeit without reaching
statistical difference (P = 0.07). As shown in Table 1, the OA-
induced changes in PAOP, Pmo, and RVSWI remained unaf-
fected by rhAPC. We noticed no significant changes in
LVSWI upon infusion of OA.
Oxygenation variables, including partial tension of oxygen in
arterial blood (PaO2) and mixed venous oxygen saturation
(SvO2), declined and AaPO2 increased after infusion of OA
but improved significantly in animals exposed to rhAPC (Fig-
ure 2 and Table 2). The OA-induced increase in Qs/Qt (P <
0.05) (Table 2) tended to be reduced under exposure to
rhAPC (P = 0.08) in parallel with increases in arterial oxygen
saturation (SaO2) and pH (P = 0.08 and 0.06, respectively),
albeit without reaching significant intergroup differences. We
noticed no effect of OA on partial tension of carbon dioxide in
arterial blood (PaCO2), blood temperature, and hemoglobin
concentration, and rhAPC did not influence any of these vari-
ables (Table 2). In both groups exposed to OA, we noticed a
decline in DO2 in comparison with baseline whereas an intra-
group decrease in VO2 was observed only in the rhAPC-
treated animals, but with no significant intergroup difference
(Table 2).
Discussion
The present investigation has shown that simultaneous admin-
istration of rhAPC ameliorates OA-induced lung injury. The
rise in pulmonary artery pressure, the evolvement of lung
edema, and the derangement of arterial oxygenation subse-
quent to intravenous bolus infusion of OA all improved signifi-
cantly during co-administration of rhAPC in our ovine model of
ALI.
The lung injury that we observed after infusion of OA had the
same characteristics as noticed in several previous studies of
this agent on larger animals, including sheep [5]. The cardio-
vascular instability (including the decrease in CI and the incre-
ments in pulmonary vascular pressure and RAP), the
evolvement of pulmonary edema, and the reduction of arterial
and mixed venous oxygenation subsequent to administration
of OA are consistent with previous reports of this type of lung
injury [25]. In animals exposed to rhAPC as co-treatment, the
OA-induced increments in PAP and RAP decreased and
PaO2 increased significantly. Similar observations have been
made under exposure to rhAPC in other models of lung injury
in sheep [16-18]. The nearly 30% decrease in oxygen delivery
was caused mainly by a combined decline in SaO2 and CI with
OA alone and almost solely by a decrease in CI in the
OA+rhAPC group (Tables 1 and 2).
Our findings agree with recently reported effects of rhAPC in
other ovine models of ALI [16-18]. In these studies, the ani-
mals had been exposed to combined smoke inhalation and air-
way instillation of live bacteria [16], feces into the peritoneum
[17], or intravenously infused endotoxin [18]. All three of the
investigations demonstrated improved arterial oxygenation
and dampened pulmonary hypertension in animals treated
with rhAPC. However, only sheep subjected to peritoneal sep-
sis or endotoxin infusion presented with reduced extravascular
lung water [17,18]. In contrast, Richard and colleagues [20],
studying OA-induced lung injury in anesthetized mechanically
ventilated pigs, found no beneficial effects of rhAPC given as
pretreatment. In that study, pulmonary hemodynamics and
arterial oxygenation deteriorated and plasma concentrations of
IL-6 and IL-8 increased in animals subjected to infusion of
rhAPC. However, our sheep had more pronounced hypoxemia
as compared with their pig model. In addition, we suspect that
the timing of APC pretreatment might have played a role in the
outcome of the study. Possibly, the anticoagulant effects of
APC could be a disadvantage before the onset of ALI. This
suggestion is supported by investigators who found increased
lung edema formation in rats subjected to intratracheal instilla-
tion of live Pseudomonas aeruginosa and co-administration of
rhAPC [21]. These authors speculate that initial fibrin deposi-
tion might have sealed off the lung vasculature of non-treated
animals, thereby reducing endothelial leakage.
Determination of EVLWI by means of the transpulmonary ther-
modilution technique is still debated. Our group and others
have compared transpulmonary thermodilution with both the
thermo-dye dilution technique and postmortem gravimetry and
demonstrated close correlations [26-28].
The mechanism by which APC improves OA-induced lung
injury is puzzling. Experimental studies have demonstrated that
neutrophils rapidly enter the pulmonary parenchyma after initi-
ation of ALI via different mechanisms, such as hypovolemic
shock [29], intestinal ischemia/reperfusion [30], or administra-
tion of endotoxin [29,31]. Thus, pulmonary neutrophil infiltra-
tion seems to be an important contributor to lung inflammation
of various etiologies [32]. Inhibition of neutrophil chemotaxis
and monocyte production of pro-inflammatory cytokines have
been proposed to contribute to the beneficial effects of APC
in sepsis and ALI [18,33-36]. However, in OA-induced ALI,
neutrophil depletion does not seem to significantly affect the
course of injury [37]. Early investigators noticed that OA trig-
gers permeability edema in isolated dog lungs to which the
perfusate had been depleted of blood components [38].
Therefore, most likely, the protective effects of APC on OA-
induced lung injury result from intervention on other inflamma-Critical Care    Vol 12 No 6    Waerhaug et al.
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Table 1
Effects of recombinant human activated protein C on oleic acid-induced changes in systemic and pulmonary hemodynamics in 
awake sheep
Time
0 hours 1 hour 2 hours
MAP, mm Hg
Sham 99 ± 4 99 ± 5 98 ± 5
OA 94 ± 3 102 ± 2 104 ± 3†a
OA+rhAPC 94 ± 3 99 ± 3 98 ± 4
CI, L/min per m2
Sham 5.8 ± 0.2 5.5 ± 0.2 5.3 ± 0.2
OA 6.3 ± 0.3 4.8 ± 0.4a 4.7 ± 0.5
OA+rhAPC 5.8 ± 0.4 4.5 ± 0.3a 4.2 ± 0.3a
SVRI, dynessecm2/cm5
Sham 1,627 ± 58 1,497 ± 97 1,479 ± 153
OA 1,231 ± 65 1,870 ± 320 1,696 ± 130a
OA+rhAPC 1,326 ± 69 1,734 ± 132a 2,085 ± 220a
PAOP, mm Hg
Sham 9 ± 0 8 ± 0 9 ± 1
OA 9 ± 0 13 ± 1a 13 ± 1a
OA+rhAPC 8 ± 0 12 ± 1a 11 ± 1a
Pmo, mm Hg
Sham 7 ± 0 7 ± 0 7 ± 0
OA 7 ± 1 10 ± 1 12 ± 1a
OA+rhAPC 7 ± 1 11 ± 1a 10 ± 1a
PVRI, dynessecm2/cm5
Sham 112 ± 12 134 ± 15 136 ± 9
OA 104 ± 8 333 ± 59a 300 ± 39a
OA+rhAPC 132 ± 8b 233 ± 25a 231 ± 28a
HR, beats per minute
Sham 104 ± 6 103 ± 6 93 ± 6
OA 109 ± 5 106 ± 12 104 ± 12
OA+rhAPC 99 ± 6 95 ± 8 84 ± 5a
SVI, mL/beat per m2
Sham 58 ± 4 55 ± 2 60 ± 6
OA 59 ± 5 48 ± 5 47 ± 6
OA+rhAPC 58 ± 5 49 ± 4a 50 ± 4a
LVSWI, gm/m2
Sham 70 ± 4 67 ± 3 71 ± 2
OA 69 ± 8 57 ± 5 59 ± 8
OA+rhAPC 68 ± 3 57 ± 4 59 ± 5
RVSWI, gm/m2
Sham 11 ± 1 11 ± 0 12 ± 1
OA 12 ± 1 17 ± 2a 15 ± 1
OA+rhAPC 11 ± 1 15 ± 1 14 ± 1
Values are presented as mean ± standard error of the mean. Sham refers to sham-operated sheep (n = 6), OA refers to sheep receiving infusion 
of oleic acid (n = 8), and OA+rhAPC refers to sheep receiving oleic acid and recombinant human activated protein C (n = 8). aP < 0.05 from t = 
0 hours. bP < 0.05 between OA and the OA+rhAPC groups. CI, cardiac index; HR, heart rate; LVSWI, left ventricular stroke work index; MAP, 
mean arterial pressure; PAOP, pulmonary artery occlusion pressure; Pmo, pulmonary micro-occlusion pressure; PVRI, pulmonary vascular 
resistance index; RVSWI, right ventricular stroke work index; SVI, stroke volume index; SVRI, systemic vascular resistance index.Available online http://ccforum.com/content/12/6/R146
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Figure 1
Changes in pulmonary artery pressure (PAP), right atrial pressure  (RAP), and extravascular lung water index (EVLWI) in awake instru- mented sheep subjected to intravenous bolus injection of oleic acid  (OA) and co-administration of recombinant human activated protein C  (rhAPC) Changes in pulmonary artery pressure (PAP), right atrial pressure 
(RAP), and extravascular lung water index (EVLWI) in awake instru-
mented sheep subjected to intravenous bolus injection of oleic acid 
(OA) and co-administration of recombinant human activated protein C 
(rhAPC). In the figure, OA refers to the oleic acid-alone group (n = 8), 
OA+rhAPC refers to the rhAPC-treated OA group (n = 8), and sham 
refers to sham-operated animals (n = 6). Data are presented as mean ± 
standard error of the mean. *P < 0.05 between OA and OA+rhAPC 
groups; †P < 0.05 from t = 0 hours in the OA group; ‡P < 0.05 from t = 
0 hours in the OA+rhAPC group.
Table 2
Effects of recombinant human activated protein C on oleic 
acid-induced changes in oxygen-related variables and body 
temperature in awake sheep
Time
0 hours 2 hours
SaO2, percentage
Sham 99 ± 0 99 ± 0
OA 98 ± 1 88 ± 5a
OA+rhAPC 99 ± 1 97 ± 1
AaPO2, mm Hg
Sham 29 ± 8 27 ± 7
OA 33 ± 8 54 ± 10a
OA+rhAPC 28 ± 13 34 ± 12b
DO2, mL/min per m2
Sham 818 ± 78 705 ± 53
OA 825 ± 39 600 ± 56a
OA+rhAPC 805 ± 71 566 ± 31a
VO2, mL/min per m2
Sham 334 ± 38 258 ± 41
OA 316 ± 34 278 ± 110
OA+rhAPC 316 ± 75 214 ± 51a
O2ER, percentage
Sham 38 ± 5 34 ± 3
OA 38 ± 2 47 ± 4
OA+rhAPC 40 ± 1 39 ± 2
PaCO2, kPa
Sham 37 ± 2 35 ± 2
OA 36 ± 1 41 ± 4
OA+rhAPC 35 ± 1 40 ± 2
Qs/Qt
Sham 0.042 ± 0.009 0.062 ± 0.018
OA 0.062 ± 0.014 0.246 ± 0.080a
OA+rhAPC 0.045 ± 0.016 0.087 ± 0.027
Arterial pH
Sham 7.51 ± 0.02 7.52 ± 0.01
OA 7.50 ± 0.01 7.44 ± 0.02
OA+rhAPC 7.51 ± 0.01 7.50 ± 0.02
Hemoglobin, g/dL
Sham 10 ± 1 10 ± 0
OA 10 ± 0 11 ± 0
OA+rhAPC 10 ± 0 10 ± 0
Body temperature, °C
Sham 40.0 ± 0.2 39.5 ± 0.4
OA 39.3 ± 0.3 39.3 ± 0.3
OA+rhAPC 39.4 ± 0.1 39.3 ± 0.1
Values are presented as mean ± standard error of the mean. Sham 
refers to the sham-operated sheep (n = 6), OA refers to sheep 
receiving infusion of oleic acid (n = 8), and OA+rhAPC refers to 
sheep receiving oleic acid and recombinant human activated protein 
C (n = 8). aP < 0.05 from t = 0 hours. bP < 0.05 between OA and 
the OA+rhAPC groups. AaPO2, alveolar-arterial oxygen tension 
difference; DO2, oxygen delivery index; O2ER, oxygen extraction 
ratio; PaCO2 arterial partial pressure of carbon dioxide; Qs/Qt, 
venous admixture; SaO2, arterial oxygen saturation; VO2, oxygen 
consumption index.Critical Care    Vol 12 No 6    Waerhaug et al.
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tory pathways. It has been demonstrated that OA activates
both the endothelin [39] and the eicosanoid pathways, includ-
ing increased secretory phospholipase A2 [40] and thrombox-
ane A2 [41-44]. Moreover, in vitro studies have revealed that
APC causes a dose-dependent inhibition of interferon-
induced expression of phospholipase A2 [45] and upregula-
tion of cyclooxygenase II expression in endothelial cells [46].
OA may also promote ALI by increasing the ratio between
angiotensin-converting enzymes I and II [47], upregulating
inducible nitric-oxide synthase (iNOS), and inhibiting alveolar
epithelial Na,K-ATPase activity [48]. In rats subjected to cecal
ligation and puncture, the investigators found that depletion of
protein C was associated with lung injury, upregulation of
iNOS, and angiotensin-converting enzyme I/II ratio, all
changes that were antagonized by administration of APC [49].
When the results of this study are evaluated, some limitations
must be taken into account. First, hemodynamic and volumet-
ric monitoring in animals subjected to respiratory distress is
particularly challenging awake and may have contributed to
the relatively large variations we noticed in some of the param-
eters. Second, in other ovine studies of sepsis or endotoxemia
[16-18], effects appeared 4 to 6 hours after starting the infu-
sion of rhAPC, so we cannot exclude the possibility that the
observation time was too short for some variables to display
significant intergroup differences. The reason for not prolong-
ing the experiments beyond 2 hours was that most variables
changed maximally within 1 hour and then declined to reach
baseline after 3 to 4 hours. Third, there is a possibility that the
study was too underpowered to show differences in all varia-
bles as early as at 2 hours. Thus, Qs/Qt, SaO2, oxygen extrac-
tion ratio (O2ER), pH, HR, Pmo, and PVRI all tended to
improve in sheep receiving rhAPC (P = 0.06 to 0.08) alone,
although without reaching statistical significance. As far as
PVRI is concerned, lack of effect of rhAPC eventually could be
caused by a significantly higher value at baseline compared
with OA alone (Table 1). When we designed the study, we had
no information about effects of rhAPC on this particular lung
injury model which could be used in a power analysis of sam-
ple sizes. However, by using the present data, a retrospective
analysis revealed that all of the latter variables could be
expected to change significantly at a power of 80% with 10
animals in each group, but animal welfare and ethical reasons
motivated us to keep the experimental groups as small as pos-
sible.
Conclusion
The present study demonstrates that rhAPC administered as
co-treatment ameliorates ovine OA-induced lung injury by
reducing pulmonary edema and improving oxygenation and
pulmonary hemodynamics. However, further studies are war-
ranted to elucidate the mechanisms by which APC counter-
acts the OA-induced lung injury.
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